Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2025-01-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41571-024-00984-xPMID 39820025
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee

  2024cited by this paper
• Novel T cell exhaustion gene signature to predict prognosis and immunotherapy response in thyroid carcinoma from integrated RNA-sequencing analysis

  2024influential reference
• Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy

  2024cited by this paper
• Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity

  2024cited by this paper
• Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity.

  2024cited by this paper
• T cell dysfunction and therapeutic intervention in cancer

  2024cited by this paper
• Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.

  2024cited by this paper
• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

  2023cited by this paper
• Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma.

  2023cited by this paper
• Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers

  2023cited by this paper
• Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

  2023cited by this paper
• Intratumoral dendritic cell–CD4^+ T helper cell niches enable CD8^+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

  2023cited by this paper
• Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

  2023cited by this paper
• Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer

  2023cited by this paper
• Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers.

  2023cited by this paper
• Immune checkpoint therapy-current perspectives and future directions.

  2023cited by this paper
• Artificial intelligence biomarkers for digital oncology: a case study of tumor-infiltrating lymphocytes in melanoma

  2023cited by this paper
• Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).

  2023influential reference
• Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop

  2023cited by this paper
• Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer.

  2023cited by this paper
• Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline

  2023cited by this paper
• Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer

  2022cited by this paper
• Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade

  2022cited by this paper
• Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response.

  2022cited by this paper
• Signatures of recent activation identify a circulating T cell compartment containing tumor-specific antigen receptors with high avidity

  2022cited by this paper
• CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer

  2022cited by this paper
• Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

  2022influential reference
• Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

  2022influential reference
• Clinical implications of T cell exhaustion for cancer immunotherapy

  2022cited by this paper
• Tumour-infiltrating lymphocytes: from prognosis to treatment selection

  2022cited by this paper
• Localization of T cell clonotypes using the Visium spatial transcriptomics platform

  2022cited by this paper
• Imaging immunity in patients with cancer using positron emission tomography

  2022cited by this paper
• Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions

  2022cited by this paper
• Intratumoral CD8+ T cells as a potential positive predictor of chemoimmunotherapy response in PD-L1-negative advanced gastric cancer patients: a retrospective cohort study

  2022cited by this paper
• Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

  2022cited by this paper
• Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma

  2022cited by this paper
• Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.

  2022cited by this paper
• B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome

  2022cited by this paper
• Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.

  2022influential reference
• Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response

  2021cited by this paper
• Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

  2021cited by this paper
• Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer

  2021cited by this paper
• Intra-tumoral CD39+CD8+ T cells predict response to PD-1/PD-L1 blockade in patients with NSCLC.

  2021cited by this paper
• Turning cold tumors into hot tumors by improving T-cell infiltration

  2021influential reference
• CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

  2021cited by this paper
• Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

  2021influential reference
• Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

  2021cited by this paper
• A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy.

  2021influential reference
• Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.

  2021cited by this paper
• Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas

  2021cited by this paper
• Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

  2021cited by this paper
• Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer

  2021cited by this paper
• Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer.

  2021influential reference
• Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy

  2021cited by this paper
• Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial

  2021cited by this paper
• Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

  2021influential reference
• Engineering enhanced CAR T-cells for improved cancer therapy

  2021cited by this paper
• Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade

  2021cited by this paper
• Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation

  2021cited by this paper
• Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

  2021cited by this paper
• A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response

  2021cited by this paper
• Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses.

  2021cited by this paper
• The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

  2020cited by this paper
• Tumor-infiltrating lymphocytes in the immunotherapy era

  2020cited by this paper
• CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

  2020cited by this paper
• Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

  2020cited by this paper
• Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

  2020cited by this paper
• B cells are associated with survival and immunotherapy response in sarcoma

  2020cited by this paper
• 3D histopathology of human tumours by fast clearing and ultramicroscopy

  2020cited by this paper
• Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

  2020cited by this paper
• Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

  2020cited by this paper
• Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

  2020cited by this paper
• Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

  2020cited by this paper
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

  2020cited by this paper
• TIMER2.0 for analysis of tumor-infiltrating immune cells

  2020cited by this paper
• Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

  2020influential reference
• Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization

  2020cited by this paper
• Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

  2020cited by this paper
• Tertiary lymphoid structures improve immunotherapy and survival in melanoma

  2020cited by this paper
• Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.

  2020cited by this paper
• Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

  2020cited by this paper
• Microsatellite instability: a review of what the oncologist should know

  2020cited by this paper
• Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer

  2020cited by this paper
• Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma

  2020cited by this paper
• Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

  2020cited by this paper
• Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

  2020cited by this paper
• B cells and tertiary lymphoid structures promote immunotherapy response

  2020influential reference
• The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

  2020cited by this paper
• The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

  2020influential reference
• CD8+ T cell states in human cancer: insights from single-cell analysis

  2020cited by this paper
• Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

  2020cited by this paper
• Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

  2020cited by this paper
• Peripheral T cell expansion predicts tumour infiltration and clinical response

  2020cited by this paper
• Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

  2019cited by this paper
• The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

  2019cited by this paper
• Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology

  2019cited by this paper
• Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer

  2019cited by this paper
• Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

  2019cited by this paper
• Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

  2019cited by this paper
• Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

  2019cited by this paper

• Advances in Melanoma Diagnosis Research

  2026cites this paper
• Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets.

  2026cites this paper
• Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges

  2026cites this paper
• Integrated and clinical validation of helicase-like transcription factor as a biomarker for hepatocellular carcinoma

  2026cites this paper
• Association of the neutrophil to lymphocyte ratio and clinical outcomes in cancers: a systematic review and meta-analysis.

  2026cites this paper
• Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer.

  2026cites this paper
• Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines.

  2026cites this paper
• Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer

  2026cites this paper
• Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies

  2026cites this paper
• AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma.

  2025cites this paper
• Anti-TNFR2 antibody and HMGN1 combined with TIL cell therapy inhibits colorectal cancer progression by enhancing immune response.

  2025cites this paper
• Smoking habit and long-term colorectal cancer incidence by exome-wide mutational and neoantigen loads: evidence based on the prospective cohort incident-tumour biobank method

  2025cites this paper
• Mapping breast cancer research on monoclonal antibodies: a data-driven approach using VOSviewer, Bibliometrix, and CiteSpace

  2025cites this paper
• Advanced single‐cell RNA sequencing in tumor immunology

  2025cites this paper
• Advances and obstacles of T cell-based immunotherapy in gynecological malignancies

  2025cites this paper
• Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model

  2025cites this paper
• Spatial transcriptomics and scRNA-seq: decoding tumor complexity and constructing prognostic models in colorectal cancer

  2025cites this paper
• Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer

  2025cites this paper
• The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives

  2025cites this paper
• Tumour-Infiltrating Lymphocytes, Tumour Cell Density, and Response to Neoadjuvant Short-Course Radiotherapy in Rectal Cancer: A Translational Sub-Study from the MRC CR07 Clinical Trial

  2025cites this paper
• Prediction of neoadjuvant therapy response in breast cancer based on interpretable artificial intelligence

  2025cites this paper
• Down-regulation and reduced surface-presentation of neoantigens in cancer stem cells decide the fate of cancer immunotherapy: An in-silico mechanistic hypothesis

  2025cites this paper
• AI-Informed Computational Pathology Classifier Predicts Outcomes across Treatment Modalities in Muscle-Invasive Urothelial Carcinoma.

  2025cites this paper
• Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI

  2025cites this paper
• Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential

  2025cites this paper
• Chemotherapy Liberates a Broadening Repertoire of Tumor Antigens for TLR7/8/9-Mediated Potent Antitumor Immunity

  2025cites this paper
• Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

  2025cites this paper
• Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors

  2025cites this paper
• Interleukin 12-tethered nano-aluminum adjuvant orchestrates environmental immunomodulation to empower cytotoxic T cells against solid tumors

  2025cites this paper
• Targeted Hyaluronan Degradation Enhanced Tumor Growth Inhibition in Gastrointestinal Cancer Models

  2025cites this paper
• CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS.

  2025cites this paper
• The promise of TIL therapy for glioblastoma.

  2025cites this paper
• Current landscape of cross-line immune checkpoint blockade for cancer treatment.

  2025cites this paper
• Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma.

  2025cites this paper
• Breaking New Ground in Cervical Metastatic Carcinoma of Unknown Primary: Neoadjuvant Immunochemotherapy’s Pathologic Regression and Survival Advantage

  2025cites this paper
• Protocol to investigate fibroblastic reticular cell-immune cell interaction in human lung cancer

  2025cites this paper
• Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors

  2025cites this paper
• Antibody–Drug Conjugates and Beyond: Next-Generation Targeted Therapies for Breast Cancer

  2025cites this paper
• Discrepant CD3+ TILs in PD-L1–Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy

  2025cites this paper
• Conceptualization of an Ex Vivo Organ Culture (EVOC) Model for Human Seminoma: A Pilot Study

  2025cites this paper
• CCCdb: a comprehensive manually curated database for cell–cell communication in human and mouse

  2025cites this paper
• Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review

  2025cites this paper
• A new marker for predicting sentinel lymph node metastasis in early (cT1-2N0) breast cancer: Tumor-infiltrating lymphocytes (TILs)

  2025cites this paper
• Putting cancer immunotherapy into spatial context in the clinic

  2025cites this paper
• Pathogenomic fingerprinting to identify associations between tumor morphology and epigenetic states.

  2025cites this paper
• Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy

  2025cites this paper
• Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping

  2025cites this paper
• Unlocking T‐Cell Plasticity in the Tumor Microenvironment: Implications for Cancer Progression and Therapeutic Strategies

  2025cites this paper
• Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis.

  2025cites this paper
• Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting

  year unknowncites this paper